image description

Tag: Monash University

Lupus Research Alliance and Lupus Therapeutics Response to Positive Data from Phase 2 Study on Potential First-in-class Lupus Treatment

June 1, 2022 The Lupus Research Alliance (LRA) and its clinical trial arm Lupus Therapeutics congratulate Bristol Myers Squibb (BMS) on new positive results from a Phase 2 trial of its investigational agent deucravacitinib for the treatment of systemic lupus erythematosus (SLE). Deucravacitinib is a potentially first-in-class inhibitor of Tyrosine kinase 2 (TYK2), which regulates […] Read More

Lupus Research Lifted Up in Everyday Health

May 27, 2021 Funding innovative research year-round is the most meaningful way the Lupus Research Alliance Lifts Up Lupus with the promise of better treatments and one day a cure. This excellent article in EVERYDAY HEALTH reports on eight of the most important discoveries in lupus of the past year, virtually all of which got […] Read More

LRA Researchers Star at ACR/ARP – Part 2

Last week we gave you only half the story of what scientists funded by the Lupus Research Alliance (LRA) shared at 2019 ACR/ARP. So many studies were presented that we needed to bring you Part 2 to expand our coverage of the major discoveries your donations have made possible. And a Part 3 is yet […] Read More

Treat-to-Target is Feasible and Beneficial in Lupus

September 19, 2019 Treating patients with lupus until they reach specific health goals can reduce disease flares and prevent organ damage, according to a research team co-led by Professor Eric F. Morand, at Monash University in Australia and past recipient of the Distinguished Innovator Award from the Lupus Research Alliance (LRA). This study is important […] Read More